Navigation Links
Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Date:12/7/2009

is.href );" target="_blank" title="MM-121">MM-121, a first-in-class ErbB3 antagonist, and MM-111, a bispecific antibody targeting ErbB2 and ErbB3. Both candidates are in Phase 1 development and are expected to enter Phase 2 in 2010.

Hermes was founded in 1998 by a group of leading cancer physicians and scientists at the University of California, San Francisco, to develop lipidic nano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy. Hermes’ lead candidate, MM-398, is a nanoliposomal formulation of CPT-11 that is currently in Phase 2 trials with a partner for multiple cancer indications (under the designation of PEP02). Merrimack expects to initiate clinical development with the next Hermes product candidate, MM-302, an antibody-targeted lipidic nano-carrier for cancer therapy, in 2010. Merrimack is privately-held and based in Cambridge, Massachusetts.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in clinical development. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and w
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... 17, 2014 Once more, EMAAR ... larger packaged waste water treatment plant to phase one ... City (KAEC). Two years ago Bioshaft successfully supplied and ... serving two residential towers with an occupancy of 900 ... quarter million gallons per day and was signed on ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... Capital Investments,Inc. (AMEX: MGT ), a technology ... sector, today reported financial results,for the first quarter ... on,strategic milestones., Tim Paterson-Brown, MGT Chairman and ... turning point for our subsidiaries, Medicsight and,Medicexchange. In ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... Rodman & Renshaw 5th Annual Global,Healthcare Conference on Tuesday, ... Beach Plaza Hotel in Monte Carlo, Monaco., The ... be,accessed under "Calendar of Events" in the Idenix Investor ...
... MedQuist Inc.,(Pink Sheets: MEDQ), the largest Medical Transcription Service ... its Form 10-Q quarterly,report with the U.S. Securities and ... Revenue for the first quarter of 2008 was $83.7M ... decrease in revenue of $5.4M or 6% from,the prior ...
Cached Biology Technology:MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments 2MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments 3MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments 4MedQuist Reports First Quarter 2008 Results 2MedQuist Reports First Quarter 2008 Results 3MedQuist Reports First Quarter 2008 Results 4MedQuist Reports First Quarter 2008 Results 5MedQuist Reports First Quarter 2008 Results 6MedQuist Reports First Quarter 2008 Results 7MedQuist Reports First Quarter 2008 Results 8MedQuist Reports First Quarter 2008 Results 9
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... a Tiger,s feet were built the same way as a mongoose,s ... feet to support the big cat,s weight. But they,re not. ... feet are put together across the four-legged animal kingdom, but until ... of the foot that bear the brunt of the animal,s walking ...
... advance toward scavenging energy from walking, breathing, and other ... phones and heart pacemakers. In a study in ACS, ... of flexible, biocompatible rubber films for use in implantable ... used, for instance, to harvest energy from the motion ...
... research suggests that nitric oxide may play a role in ... Mittal et al, "Inhibition of inducible nitric oxide controls pathogen ... coli K1 in neonatal meningitis," appears in the March ... Bacterial meningitis, or inflammation of the membranes that ...
Cached Biology News:The bigger the animal, the stiffer the 'shoes' 2Treating neonatal meningitis -- is nitric oxide a foe or a friend to bacteria? 2
MHC Volumes 1 & 2...
...
... Johnstone and M.W. Turner (1997). • ... methods used in the production of ... in immunoassays, the standardisation of antibodies ... including amplification systems, enzyme immunoassays for ...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Biology Products: